MedTrace Logo

A Study for PRO of CML in Real Word

NCT05092048 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2021-10-25

No results posted yet for this study

Summary

Successful outcomes in CML require both prolonged adherence to oral TKI therapy by patients and careful monitoring of treatment responses by their physicians. Patient Reported Outcomes(PRO) assessment is important to facilitate decisions in the current treatment landscape of CML.

Conditions

  • CML (Chronic Myelogenous Leukemia)

Interventions

OTHER

questionnaire

PHQ-9 and GAD-7 questionnaire

Sponsors & Collaborators

  • xuna

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-22
Primary Completion
2022-09-30
Completion
2022-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05092048 on ClinicalTrials.gov